Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.

Rami, Avina; DuBois, Steven G; Campbell, Kevin

Rami, Avina; DuBois, Steven G; Campbell, Kevin.

Affiliation

Rami A; Harvard Medical School, Boston, MA, USA.
DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
Campbell K; Children's Mercy Hospitals and Clinics, Kansas City, MO, USA.

Clin Trials ; 21(2): 211-219, 2024 04.

Article in En | MEDLINE | ID: mdl-37961910

Subject(s)

Antineoplastic Agents; Neoplasms; Humans; Antineoplastic Agents/toxicity; Dose-Response Relationship, Drug; Neoplasms/drug therapy; Medical Oncology; Research Design; Clinical Trials, Phase I as Topic

Key words

Phase I; clinical trial; dose-limiting toxicity; oncology; subsequent cycle

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: Clin Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2024 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google